Glycyrrhetinic acid-modified chitosan nanoparticles enhanced the effect of 5-fluorouracil in murine liver cancer model via regulatory T-cells [Retraction]
Cheng M, Xu H, Wang Y, et al. Drug Des Devel Ther. 2013;7:1287–1299. It has come to the notice of this journal that the published paper:Cheng M, Xu H, Wang Y, et al. Glycyrrhetinic acid-modified chitosan nanoparticles enhanced the effect of 5-fluorouracil in murine liver cancer m...
Main Authors: | Cheng M, Xu H, Wang Y, Chen H, He B, Gao X, Li Y, Han J, Zhang Z |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2014-07-01
|
Series: | Drug Design, Development and Therapy |
Online Access: | http://www.dovepress.com/retraction-glycyrrhetinic-acid-modified-chitosan-nanoparticles-en-peer-reviewed-article-DDDT |
Similar Items
-
Glycyrrhetinic acid-modified chitosan nanoparticles enhanced the effect of 5-fluorouracil in murine liver cancer model via regulatory T-cells
by: Cheng M, et al.
Published: (2013-10-01) -
Optimized synthesis of glycyrrhetinic acid-modified chitosan 5-fluorouracil nanoparticles and their characteristics
by: Cheng M, et al.
Published: (2014-01-01) -
Synthesis of Glycyrrhetinic Acid-Modified Chitosan 5-Fluorouracil Nanoparticles and Its Inhibition of Liver Cancer Characteristics in Vitro and in Vivo
by: Jiang Han, et al.
Published: (2013-09-01) -
A novel glycyrrhetinic acid-modified oxaliplatin liposome for liver-targeting and in vitro/vivo evaluation
by: Chen J, et al.
Published: (2015-04-01) -
Glycyrrhetinic acid-functionalized mesoporous silica nanoparticles as hepatocellular carcinoma-targeted drug carrier
by: Lv Y, et al.
Published: (2017-06-01)